###### Key messages

-   Patients with pulmonary *Mycobacterium avium* complex (MAC) disease are often co-infected with various other pathogenic microorganisms, but the factors associated with microorganism co-infection in patients with pulmonary MAC remain unclear.

-   Patients with pulmonary MAC disease frequently had chronic co-infections with pathogenic microorganisms such as methicillin-sensitive *Staphylococcus aureus*, *Pseudomonas aeruginosa* and *Aspergillus*, and the adjusted risk factors for chronic co-infection were chronic obstructive pulmonary disease (COPD) and pulmonary *M. intracellulare* disease.

-   Chronic co-infection is common in patients with pulmonary MAC disease, and COPD and pulmonary *M. intracellulare* disease increase the risk of co-infection.

Introduction {#s1}
============

As the prevalence of pulmonary non-tuberculous mycobacterial (NTM) disease, especially pulmonary *Mycobacterium avium* complex (MAC) disease, has been increasing worldwide,[@R1] more patients have an opportunity to be followed in a medical institution.[@R4] [@R5] Pulmonary MAC disease has a prolonged course and often manifests as bronchiectasis and cavitation in high-resolution CT (HRCT) images.[@R6] In patients susceptible to bronchiectasis, chronic inflammation causes damage primarily to the bronchi. Damaged airways are susceptible to infection, resulting in further destruction and dilation of the bronchi and leading to bronchiectasis.[@R7] [@R8] NTM infection has been shown to stimulate the development of or worsen pre-existing bronchiectasis, although causality has not been definitively established.[@R9]

Chronic infections with bacteria such as *Pseudomonas aeruginosa* and *Haemophilus influenzae* are associated with bronchiectasis and cystic fibrosis, causing recurrent exacerbations of these diseases and leading to lung function decline and premature death.[@R12] Although these pathogenic microorganisms can be isolated intermittently, chronic infections are known to have a higher clinical impact.[@R15]

During the course of pulmonary NTM disease, co-infections with various bacteria other than NTM such as *P. aeruginosa, H. influenzae* and *Aspergillus* are occasionally observed.[@R19] [@R20] However, previous studies of these infections included a relatively small number of participants with MAC disease, and patients with single NTM isolates were most likely only temporarily colonised.[@R6] Furthermore, although some host traits, such as chronic lung disease and autoimmune disease, and the use of immunosuppressive agents are known risk factors for infection in patients with bronchiectasis and cystic fibrosis,[@R18] [@R21] [@R22] the factors associated with microorganism co-infections in patients with pulmonary MAC remain unclear.

The aim of this study was to determine the prevalence of co-infection with non-MAC pathogenic microorganisms and to identify risk factors for co-infection among clinical, microbiological and radiological findings in patients with pulmonary MAC disease.

Methods {#s2}
=======

Study design and population {#s2a}
---------------------------

This was a retrospective cohort study of 645 patients with pulmonary MAC, who fulfilled the American Thoracic Society diagnostic criteria and who visited the Kyoto University Hospital from January 2001 to May 2013.[@R6] We reviewed patient characteristics, microbiological results and chest (HRCT) findings from institutional medical records. We excluded 370 patients: 295 patients who were unable to provide sputum samples at least two times in a year, medical history and/or CT scan data; 74 patients who were followed up for less than 12 months from the first visit to the last visit and 1 patient who had complications with disseminated MAC infection and HIV infection. Finally, we analysed 275 patients with pulmonary MAC in this study. Laboratory and HRCT data from patients with any co-infecting microorganism were collected around the time that the co-infecting microorganism was first isolated, and the data collected from patients without co-infection by microorganisms were collected at the time of the first visit.

Microbiological classification {#s2b}
------------------------------

We defined chronic pathogenic microorganism co-infection (chronic co-infection) as the isolation of non-MAC potential pathogens from two or more sputum samples taken on two separate visits at least 3 months apart. Cultures did not necessarily have to be consecutive. Patients were defined as having an intermittent pathogenic microorganism co-infection (intermittent co-infection) when the potential pathogen had been isolated only once in the past. Patients with no pathogenic microorganism co-infection (no co-infection) did not have any potential pathogens isolated from any of the sputum samples at any time.[@R15] Since *Staphylococcus aureus* often colonises the human oropharynx, the sputum quality was checked according to the Geckler classification to distinguish between infection and colonisation.[@R23] Only sputum with a Geckler classification of 4 or 5 was selected for analysis. In addition, making a clear distinction between *Aspergillus* infection and colonisation is not feasible. Therefore, we have chosen to use the term infection throughout this article.[@R18]

Radiological findings {#s2c}
---------------------

We assessed four cardinal HRCT findings (nodule, bronchiectasis, cavity and consolidation). We counted the extent and location of lung involvement and thoracic abnormalities (scoliosis and pectus excavatum) in the HRCT. We classified the following four radiographic forms according to previous reports: nodular/bronchiectatic (NB), fibrocavitary (FC), NB+FC and unclassified.[@R4] One board-certified thoracic radiologist who had no prior knowledge of the patients' profiles or laboratory test results read the HRCT images.

Statistical analysis {#s2d}
--------------------

JMP V.9.0.0 was used for all statistical analyses. Group comparisons were made using the χ^2^ test or Fisher\'s exact test for categorical values and the Wilcoxon test for continuous values. To adjust for confounders, variables with a p value less than 0.05 on univariate analysis were entered into a multivariate logistic regression analysis. ORs and their respective 95% CIs were computed as estimates of relative risk. For all analyses, p values less than 0.05 were considered statistically significant.

Results {#s3}
=======

Characteristics of the study population {#s3a}
---------------------------------------

The participants were predominantly female (205 patients, 74.5%) and infected with *M. avium* (208 patients, 75.6%). The mean age at diagnosis was 61.9±11.6 years, and the mean duration of MAC disease from diagnosis was 7.2±7 years. Bronchiectasis was the most frequent host trait (234 patients, 85.1%), followed by severe pneumonia (81 patients, 29.6%), malignant disease (57 patients, 20.7%) and prior tuberculosis (34 patients, 12.4%). Since it is often difficult to distinguish which comes first, the bronchiectasis or the pulmonary MAC disease, we counted bronchiectasis as an underlying disease when it was detected in the first HRCT. Autoimmune disease was recorded in 36 patients (13.1%), with 19 (52.8%) having rheumatoid arthritis ([table 1](#BMJRESP2014000050TB1){ref-type="table"}). In the HRCT scans, nodules and bronchiectasis were the most common findings (86.2% and 85.1%), and they were predominantly located in the right middle lobe or lingula.

###### 

Characteristics of the study population

  Clinical characteristics                       n=275
  ---------------------------------------------- ------------
  Age at diagnosis, years                        61.9±11.6
  Gender (female)                                205 (74.5)
  Body mass index, kg/m^2^                       19.4±2.8
  Smoking status (never)                         219 (79.6)
  Chronic microorganism co-infection             124 (45.1)
  Intermittent microorganism co-infection        41 (14.9)
  Number of sputum samples, numbers/year         
   All patients                                  4.43±2.4
   Patients with chronic co-infection            4.51±2.4
   Patients with intermittent co-infection       4.54±2.3
  Underlying disease                             
   Bronchiectasis                                234 (85.1)
   Severe pneumonia (hospitalisation)            81 (29.6)
   COPD                                          28 (10.2)
   Asthma                                        24 (8.7)
   History of tuberculosis                       34 (12.4)
   History of malignant disease                  57 (20.7)
   Diabetes mellitus                             26 (9.5)
   Autoimmune disease                            36 (13.1)
   Rheumatoid arthritis                          19 (6.9)
   GORD symptom                                  44 (16.1)
   Use of systemic corticosteroids               22 (8.0)
   Use of immunosuppressant agent                24 (8.7)
   Use of inhaled corticosteroids                19 (6.9)
   Infected MAC strain (*Mycobacterium avium*)   208 (75.6)
   Duration of MAC disease, years                7.2±7.0

Data show either the number (%) of patients or the mean±SD.

COPD, chronic obstructive pulmonary disease; GORD, gastro-oesophageal reflux disease; MAC, *M. avium* complex.

Patients with pulmonary *M. intracellulare* were older in age and had significantly lower body mass indices. These patients more frequently had host traits of severe pneumonia, malignant disease and autoimmune disease and used more systemic corticosteroids than patients with pulmonary *M. avium* ([table 2](#BMJRESP2014000050TB2){ref-type="table"}). In the HRCT analysis, patients with pulmonary *M. intracellulare* had significantly more cavity findings and the NB+FC form of lung involvement than patients with *M. avium* ([table 2](#BMJRESP2014000050TB2){ref-type="table"}).

###### 

Characteristics and HRCT findings of patients with pulmonary *Mycobacterium avium* and *M. intracellulare*

                                            Pulmonary *M. avium* disease (n=208)   Pulmonary *M. intracellulare* disease (n=67)   p Value
  ----------------------------------------- -------------------------------------- ---------------------------------------------- ---------
  Age at diagnosis, years                   61.0±11.6                              64.7±11.5                                      0.0029
  Gender (female)                           158 (76.0)                             47 (70.2)                                      0.34
  Body mass index, kg/m^2^                  19.6±2.6                               18.7±3.2                                       0.012
  Smoking status (never)                    163 (78.4)                             56 (83.6)                                      0.36
  Chronic microorganism co-infection        87 (41.8)                              37 (55.2)                                      0.055
  Intermittent microorganism co-infection   27 (13.0)                              14 (20.9)                                      0.11
  Underlying disease                                                                                                              
   Bronchiectasis                           177 (85.1)                             57 (85.1)                                      \>0.99
   Severe pneumonia (hospitalisation)       53 (25.5)                              28 (41.8)                                      0.011
   COPD                                     22 (10.6)                              6 (9.0)                                        0.81
   Asthma                                   19 (9.1)                               5 (7.5)                                        0.81
   History of tuberculosis                  23 (11.1)                              11 (16.4)                                      0.25
   History of malignant disease             36 (17.3)                              21 (31.3)                                      0.014
   Diabetes mellitus                        19 (9.1)                               7 (10.5)                                       0.81
   Autoimmune disease                       22 (10.6)                              14 (20.9)                                      0.029
   Rheumatoid arthritis                     11 (5.3)                               8 (11.9)                                       0.092
   GORD symptom                             34 (16.4)                              10 (14.9)                                      0.77
   Use of systemic corticosteroids          12 (5.8)                               10 (14.9)                                      0.016
   Use of immunosuppressant agent           15 (7.2)                               9 (13.4)                                       0.14
   Use of inhaled corticosteroids           14 (6.7)                               5 (7.5)                                        0.79
   Duration of MAC disease, years           7.3±6.6                                7.0±8.1                                        0.34
  HRCT findings                                                                                                                   
   Nodule                                   179 (86.1)                             58 (86.6)                                      \>0.99
   Consolidation                            114 (54.8)                             38 (56.7)                                      0.78
   Bronchiectasis                           177 (85.1)                             57 (85.1)                                      \>0.99
   Cavity                                   66 (31.7)                              32 (47.8)                                      0.017
  Radiographic pattern                                                                                                            
   NB form                                  125 (60.1)                             27 (40.3)                                      0.0072
   FC form                                  17 (8.2)                               8 (11.9)                                       0.34
   NB+FC form                               48 (23.1)                              24 (35.8)                                      0.039
   Unclassified                             18 (8.7)                               8 (11.9)                                       0.47
  Thoracic abnormality                                                                                                            
   Scoliosis                                49 (23.6)                              23 (34.3)                                      0.08
   Pectus excavatum                         25 (12.0)                              6 (9.0)                                        0.66
  Location of HRCT findings                                                                                                       
   Right/left upper lobe                    157 (75.5)                             51 (76.1)                                      0.92
   Right middle lobe/lingula                189 (90.9)                             64 (95.5)                                      0.3
   Right/left lower lobe                    135 (64.9)                             57 (85.1)                                      0.0018

Data show either the number (%) of patients or the mean±SD.

COPD, chronic obstructive pulmonary disease; FC, fibrocavitary; GORD, gastro-oesophageal reflux disease; HRCT, high-resolution CT; MAC, *M. avium* complex; NB, nodular/bronchiectatic.

Type of co-infection and isolated microorganisms {#s3b}
------------------------------------------------

Of the 275 patients with pulmonary MAC, 124 (45.1%) had chronic co-infections, 41 (14.9%) had intermittent co-infections and 110 (40.0%) had no co-infection. Among the 277 detected microorganisms, methicillin-sensitive *S. aureus* (MSSA; 89 patients, 32.4%), *P. aeruginosa* (45 patients, 16.4%) and *Aspergillus* spp (29 patients, 10.5%) were the most prevalent co-pathogens. These three species were more frequently isolated from patients with a chronic co-infection than from those with an intermittent co-infection (64 and 25 patients with MSSA infection, 35 and 10 patients with *P. aeruginosa* infection and 18 and 11 patients with *Aspergillus* infection, respectively). In contrast, intermittent co-infections were observed more frequently than chronic co-infections for *Serratia marcescens* (12 and 2 patients, respectively), *Moraxella catarrhalis* (7 and 1 patients, respectively), *Acinetobacter baumannii* (6 and 1 patients, respectively) and *Klebsiella oxytoca* (2 and 0 patients, respectively) ([figure 1](#BMJRESP2014000050F1){ref-type="fig"}).

![All microorganism strains isolated from the sputum during the study period. The graph shows the number of patients with chronic and intermittent microorganism co-infections. The blue and red bars show chronic and intermittent infections, respectively (MSSA, methicillin-sensitive *Staphylococcus aureus*; MRSA, methicillin-resistant *Staphylococcus aureus*).](bmjresp2014000050f01){#BMJRESP2014000050F1}

Characteristics of patients and factors associated with chronic and intermittent co-infection {#s3c}
---------------------------------------------------------------------------------------------

Compared with patients who did not have a co-infection, chronic co-infection was significantly associated with a history of severe pneumonia, chronic obstructive pulmonary disease (COPD), rheumatoid arthritis, use of systemic corticosteroids and pulmonary *M. intracellulare* disease. Intermittent co-infection was associated with pulmonary *M. intracellulare* disease alone. There was no significant difference in the history of MAC treatment and a negative conversion rate of MAC sputum cultures during the study period between patients with chronic co-infections and those without co-infection ([table 3](#BMJRESP2014000050TB3){ref-type="table"}). There were no significant differences in the HRCT findings, the location of areas of lung involvement and thoracic abnormalities between patients with chronic or intermittent co-infection and those without co-infection. ([table 4](#BMJRESP2014000050TB4){ref-type="table"}).

###### 

Characteristics of patients with pulmonary MAC with chronic and intermittent co-infection

  Variables                                               No co-infection (n=110)   Chronic co-infection (n=124)   p Value   Intermittent co-infection (n=41)   p Value
  ------------------------------------------------------- ------------------------- ------------------------------ --------- ---------------------------------- ---------
  Age at diagnosis, years                                 61.9±11.5                 61.6±12.3                      0.91      62.8±9.7                           0.62
  Gender (female)                                         88 (80.0)                 87 (70.2)                      0.084     30 (73.2)                          0.37
  Body mass index, kg/m^2^                                19.1±2.9                  19.6±2.8                       0.37      19.8±2.5                           0.13
  Smoking status (never)                                  92 (83.6)                 93 (75.0)                      0.11      34 (82.9)                          0.92
  Underlying disease                                                                                                                                            
   Bronchiectasis                                         92 (83.6)                 108 (87.1)                     0.45      34 (82.9)                          \>0.99
   Severe pneumonia (hospitalisation)                     26 (23.6)                 45 (36.3)                      0.036     10 (24.4)                          0.92
   COPD                                                   5 (4.6)                   21 (16.9)                      0.0030    2 (4.9)                            0.99
   Asthma                                                 7 (6.4)                   14 (11.3)                      0.25      3 (7.3)                            0.99
   History of tuberculosis                                13 (11.8)                 18 (14.5)                      0.54      3 (7.3)                            0.56
   History of malignant disease                           17 (15.5)                 30 (24.2)                      0.096     10 (24.4)                          0.20
   Diabetes mellitus                                      9 (8.2)                   11 (8.9)                       0.99      6 (14.6)                           0.24
   Autoimmune disease                                     9 (8.2)                   19 (15.3)                      0.11      8 (19.5)                           0.079
   Rheumatoid arthritis                                   3 (2.7)                   12 (9.7)                       0.034     4 (9.8)                            0.087
   GORD symptom                                           17 (15.5)                 18 (14.5)                      0.86      9 (22.5)                           0.33
   Use of systemic corticosteroids                        4 (3.6)                   16 (12.9)                      0.017     2 (4.9)                            0.66
   Use of immunosuppressant agent                         5 (4.6)                   13 (10.5)                      0.14      6 (14.6)                           0.07
   Use of inhaled corticosteroids                         4 (3.6)                   13 (10.5)                      0.074     2 (4.9)                            0.73
   Infected MAC strain (*Mycobacterium intracellulare*)   16 (14.6)                 36 (29.3)                      0.0053    13 (33.3)                          0.011
   Duration of MAC disease, years                         6.3±5.0                   8.5±8.6                        0.15      5.7±5.3                            0.39
   History of MAC treatment                               76 (69.1)                 81 (65.3)                      0.54      27 (65.9)                          0.70
   MAC sputum culture conversion                          74 (67.3)                 87 (70.2)                      0.63      31 (75.6)                          0.32

Data show either the number (%) of patients or the mean±SD.

COPD, chronic obstructive pulmonary disease; GORD, gastro-oesophageal reflux disease; MAC, *M. avium* complex.

###### 

HRCT findings of patients with pulmonary *Mycobacterium avium* complex with chronic and intermittent co-infections

  Variables                    No co-infection (n=110)   Chronic co-infection (n=124)   p Value   Intermittent co-infection (n=41)   p Value
  ---------------------------- ------------------------- ------------------------------ --------- ---------------------------------- ---------
  HRCT findings                                                                                                                      
   Nodule                      89 (80.9)                 110 (88.7)                     0.095     38 (92.7)                          0.086
   Consolidation               60 (54.6)                 76 (61.3)                      0.30      16 (39.0)                          0.09
   Bronchiectasis              92 (83.6)                 108 (87.1)                     0.45      34 (82.9)                          0.99
   Cavity                      42 (38.2)                 45 (36.3)                      0.79      11 (26.8)                          0.19
  Radiographic pattern                                                                                                               
   NB form                     55 (50.0)                 71 (57.3)                      0.27      26 (63.4)                          0.14
   FC form                     14 (12.7)                 9 (7.3)                        0.19      2 (4.9)                            0.24
   NB+FC form                  28 (25.5)                 36 (29.0)                      0.54      9 (22.0)                           0.83
   Unclassified                13 (11.8)                 9 (7.3)                        0.27      4 (9.8)                            0.99
  Thoracic abnormality                                                                                                               
   Scoliosis                   28 (25.5)                 34 (27.4)                      0.73      10 (24.4)                          0.89
   Pectus excavatum            12 (10.9)                 15 (12.1)                      0.84      4 (9.8)                            0.99
  Location of HRCT findings                                                                                                          
   Right/left upper lobe       81 (73.6)                 95 (76.6)                      0.60      32 (78.1)                          0.68
   Right middle lobe/lingula   98 (89.1)                 117 (94.4)                     0.16      38 (92.7)                          0.76
   Right/left lower lobe       71 (64.6)                 91 (73.4)                      0.14      30 (73.2)                          0.32

Data show the number (%) of patients.

FC, fibrocavitary; HRCT, high-resolution CT; NB, nodular/bronchiectatic.

In the multivariate analysis, COPD (OR 4.2; 95% CI 1.6 to 13.1; p=0.0029) and pulmonary *M. intracellulare* disease (OR 2.2; 95% CI 1.1 to 4.4; p=0.026) were independently associated with chronic co-infection. Pulmonary *M. intracellulare* disease (OR 3.0; 95% CI 1.3 to 7.1; p=0.01) was also independently associated with intermittent co-infection ([table 5](#BMJRESP2014000050TB5){ref-type="table"}).

###### 

Factors associated with chronic and intermittent co-infections

  Variables                                        Chronic co-infection   Intermittent co-infection                      
  ------------------------------------------------ ---------------------- --------------------------- ------------------ ------
  Severe pneumonia                                 1.5 (0.8 to 2.7)       0.22                        --                 --
  COPD                                             4.2 (1.6 to 13.1)      0.0029                      --                 --
  Rheumatoid arthritis                             1.8 (0.38 to 9.9)      0.48                        --                 --
  Use of systemic corticosteroids                  2.1 (0.55 to 9.6)      0.28                        --                 --
  Infected *Mycobacterium intracellulare* strain   2.2 (1.1 to 4.4)       0.026                       3.0 (1.3 to 7.1)   0.01

Variables were included if the probability values were less than 0.05 by univariate analysis.

COPD, chronic obstructive pulmonary disease.

Characteristics of patients and factors associated with chronic MSSA co-infection {#s3d}
---------------------------------------------------------------------------------

COPD, the use of inhaled corticosteroids and a longer duration of MAC disease were significantly associated with chronic MSSA co-infection in patients ([table 6](#BMJRESP2014000050TB6){ref-type="table"}).

###### 

Characteristics of patients with pulmonary MCA with chronic MSSA, *Pseudomonas aeruginosa* and *Aspergillus* co-infections

  Variables                                              No co-infection (n=110)   Chronic MSSA co-infection (n=64)   p Value   Chronic *P. aeruginosa* co-infection (n=35)   p Value   Chronic *Aspergillus* co-infection (n=18)   p Value
  ------------------------------------------------------ ------------------------- ---------------------------------- --------- --------------------------------------------- --------- ------------------------------------------- ---------
  Age at diagnosis, years                                61.9±11.5                 61.4±11.8                          0.84      61.9±11.6                                     0.78      64.3±13.4                                   0.16
  Gender (female)                                        88 (80.0)                 46 (71.9)                          0.22      25 (71.4)                                     0.29      10 (55.7)                                   0.035
  Body mass index, kg/m^2^                               19.1±2.9                  19.6±2.7                           0.34      20.0±2.7                                      0.26      18.7±2.6                                    0.54
  Smoking status (never)                                 92 (83.6)                 48 (75.0)                          0.17      25 (71.4)                                     0.11      14 (77.8)                                   0.51
  Underlying disease                                                                                                                                                                                                                
   Bronchiectasis                                        92 (83.6)                 53 (82.8)                          0.89      32 (91.4)                                     0.41      15 (83.3)                                   \>0.99
   Severe pneumonia (hospitalisation)                    26 (23.6)                 20 (31.3)                          0.27      16 (45.7)                                     0.012     11 (61.1)                                   0.0034
   COPD                                                  5 (4.6)                   10 (15.6)                          0.022     10 (28.6)                                     0.0003    3 (16.7)                                    0.084
   Asthma                                                7 (6.4)                   7 (10.9)                           0.39      5 (14.3)                                      0.16      4 (22.2)                                    0.049
   History of tuberculosis                               13 (11.8)                 6 (9.4)                            0.80      4 (11.4)                                      0.99      6 (33.3)                                    0.029
  History of malignant disease                           17 (15.5)                 14 (21.9)                          0.29      10 (28.6)                                     0.083     5 (27.8)                                    0.19
  Diabetes mellitus                                      9 (8.2)                   4 (6.3)                            0.77      2 (5.7)                                       0.99      2 (11.1)                                    0.65
  Autoimmune disease                                     9 (8.2)                   4 (6.3)                            0.77      10 (28.6)                                     0.0038    5 (27.8)                                    0.028
  Rheumatoid arthritis                                   3 (2.7)                   2 (3.1)                            0.99      7 (20.0)                                      0.0019    3 (16.7)                                    0.036
  GORD symptom                                           17 (15.5)                 13 (20.3)                          0.41      4 (11.4)                                      0.78      1 (5.6)                                     0.47
  Use of systemic corticosteroids                        4 (3.6)                   3 (4.7)                            0.71      9 (25.7)                                      0.0004    6 (33.3)                                    0.0005
  Use of immunosuppressant agent                         5 (4.6)                   3 (4.7)                            0.99      7 (20.0)                                      0.0086    3 (16.7)                                    0.084
  Use of inhaled corticosteroids                         4 (3.6)                   8 (12.5)                           0.033     5 (14.3)                                      0.023     3 (16.7)                                    0.057
  Infected MAC strain (*Mycobacterium intracellulare*)   16 (14.6)                 16 (25.0)                          0.086     11 (34.3)                                     0.01      9 (50.0)                                    0.0016
  Duration of MAC disease, years                         6.3±5.0                   9.0±6.9                            0.017     8.5±10.8                                      0.96      8.1±10.2                                    0.91
  History of MAC treatment                               76 (69.1)                 37 (57.8)                          0.13      24 (68.6)                                     0.95      11 (61.1)                                   0.59
  MAC sputum culture conversion                          74 (67.3)                 46 (71.9)                          0.53      29 (82.9)                                     0.09      11 (61.1)                                   0.60

Data show either the number (%) of patients or the mean±SD.

COPD, chronic obstructive pulmonary disease; GORD, gastro-oesophageal reflux disease; MAC, *M. avium* complex; MSSA, methicillin-sensitive *Staphylococcus aureus*.

In the HRCT findings, nodule findings and the NB form were predominantly found in patients with chronic MSSA co-infection ([table 7](#BMJRESP2014000050TB7){ref-type="table"}). In the multivariate analysis, COPD (OR 4.2; 95% CI 1.3 to 15.2; p=0.017), longer duration of MAC disease (OR 2.2; 95% CI 1.2 to 4.4; p=0.017) and having nodules on the HRCT (OR 3.5; 95% CI 1.2 to 13.2; p=0.019) were significantly associated with chronic MSSA co-infection ([table 8](#BMJRESP2014000050TB8){ref-type="table"}).

###### 

HRCT findings of patients with pulmonary *Mycobacterium avium* complex with chronic MSSA, *Pseudomonas aeruginosa* and *Aspergillus* co-infections

  Variables                    No co-infection (n=110)   Chronic MSSA co-infection (n=64)   P value   Chronic *P. aeruginosa* co-infection (n=35)   P value   Chronic *Aspergillus* co-infection (n=18)   P value
  ---------------------------- ------------------------- ---------------------------------- --------- --------------------------------------------- --------- ------------------------------------------- ---------
  HRCT findings                                                                                                                                                                                           
   Nodule                      89 (80.9)                 60 (93.8)                          0.024     26 (74.3)                                     0.47      15 (83.3)                                   0.99
   Consolidation               60 (54.6)                 37 (57.8)                          0.68      24 (68.6)                                     0.14      14 (77.8)                                   0.076
   Bronchiectasis              92 (83.6)                 53 (82.8)                          0.89      32 (91.4)                                     0.41      15 (83.3)                                   0.99
   Cavity                      42 (38.2)                 18 (28.1)                          0.18      16 (45.7)                                     0.43      9 (50.0)                                    0.44
  Radiographic pattern                                                                                                                                                                                    
   NB form                     55 (50.0)                 43 (67.2)                          0.028     17 (48.6)                                     0.99      7 (38.9)                                    0.45
   FC form                     14 (12.7)                 1 (1.6)                            0.011     3 (8.6)                                       0.76      3 (16.7)                                    0.71
   NB+FC form                  28 (25.5)                 17 (26.6)                          0.87      13 (37.1)                                     0.18      6 (33.3)                                    0.48
   Unclassified                13 (11.8)                 4 (6.3)                            0.30      3 (8.6)                                       0.59      2 (11.1)                                    0.99
  Thoracic abnormality                                                                                                                                                                                    
   Scoliosis                   28 (25.5)                 16 (25.0)                          0.95      11 (31.4)                                     0.49      8 (44.4)                                    0.15
   Pectus excavatum            12 (10.9)                 8 (12.5)                           0.81      3 (8.6)                                       0.99      2 (11.1)                                    0.99
  Location of HRCT findings                                                                                                                                                                               
   Right/left upper lobe       81 (73.6)                 45 (70.3)                          0.64      27 (77.1)                                     0.82      15 (83.3)                                   0.56
   Right middle lobe/lingula   98 (89.1)                 62 (96.9)                          0.086     32 (91.4)                                     0.99      15 (83.3)                                   0.44
   Right/left lower lobe       71 (64.6)                 45 (70.3)                          0.44      33 (94.3)                                     0.0007    14 (77.8)                                   0.42

Data show the number (%) of patients.

FC, fibrocavitary; HRCT, high-resolution CT; MSSA, methicillin-sensitive *Staphylococcus aureus*; NB, nodular/bronchiectatic.

###### 

Factors associated with chronic MSSA, *Pseudomonas aeruginosa* and *Aspergillus* co-infections

  Variables                                        Chronic MSSA co-infection   Chronic *P. aeruginosa* co-infection   Chronic *Aspergillus* co-infection                                 
  ------------------------------------------------ --------------------------- -------------------------------------- ------------------------------------ -------- -------------------- -------
  Male gender                                      --                          --                                     --                                   --       2.3 (0.6 to 8.7)     0.21
  History of severe pneumonia                      --                          --                                     1.5 (0.57 to 3.8)                    0.41     3.2 (0.93 to 12.0)   0.064
  COPD                                             4.2 (1.3 to 15.2)           0.017                                  7.5 (2.1 to 31.4)                    0.0017   --                   --
  Asthma                                           --                          --                                     --                                   --       3.2 (0.53 to 18.2)   0.19
  History of tuberculosis                          --                          --                                     --                                   --       1.8 (0.37 to 7.7)    0.46
  Rheumatoid arthritis                             --                          --                                     3.4 (0.59 to 21.0)                   0.17     1.9 (0.17 to 19.5)   0.58
  Use of systemic corticosteroids                  --                          --                                     3.5 (0.74 to 18.0)                   0.11     7.1 (1.2 to 50.9)    0.034
  Use of inhaled corticosteroids                   2.7 (0.74 to 11.1)          0.13                                   4.6 (0.92 to 25.1)                   0.062    --                   --
  Infected *Mycobacterium intracellulare* strain   --                          --                                     1.8 (0.61 to 5.1)                    0.29     4.0 (1.1 to 14.5)    0.036
  Long duration of MAC disease                     2.2 (1.2 to 4.4)            0.017                                  --                                   --       --                   --
  Nodule finding                                   3.5 (1.2 to 13.2)           0.019                                  --                                   --       --                   --
  Lung involvement at lower lobe                   --                          --                                     9.9 (2.0 to 90.6)                    0.0027   --                   --

Variables were included if the probability values were less than 0.05 by univariate analysis.

COPD, chronic obstructive pulmonary disease; MAC, *M. avium* complex; MSSA, methicillin-sensitive *Staphylococcus aureus*.

Of 64 patients with chronic MSSA co-infection, 41 patients (64.1%) had a MAC-positive sputum culture. Thirty-seven patients (57.8%) had a history of MAC treatment, and only two of these patients (5.4%) had a positive MSSA sputum culture during MAC treatment. After 46 patients had converted sputum cultures of MAC, 32 patients (69.6%) had a positive MSSA sputum culture ([tables 6](#BMJRESP2014000050TB6){ref-type="table"} and [9](#BMJRESP2014000050TB9){ref-type="table"}). Thirty-two of 64 (50%) patients with chronic MSSA co-infection had received antibiotic treatment for their co-infection.

###### 

Isolation of chronic microorganisms of interest during positive MAC sputum culture, during MAC treatment and after MAC sputum conversion

                                       Chronic MSSA co-infection (n=64)   Chronic *Pseudomonas aeruginosa* co-infection (n=35)   Chronic *Aspergillus* co-infection (n=18)
  ------------------------------------ ---------------------------------- ------------------------------------------------------ -------------------------------------------
  During positive MAC sputum culture   41 (64.1)                          9 (25.7)                                               9 (50.0)
  During MAC treatment                 2 (5.4)\*                          18 (75.0)\*                                            9 (81.8)\*
  After MAC sputum conversion          32 (69.6)†                         27 (93.1)†                                             9 (81.8)†

\*MAC treatment was received in patients with chronic MSSA co-infection (n=37), chronic *P. aeruginosa* co-infection (n=24) and chronic *Aspergillus* co-infection (n=11).

†Patients with chronic MSSA co-infection (n=46), chronic *P. aeruginosa* co-infection (n=29) and chronic *Aspergillus* co-infection (n=11) converted sputum culture of MAC.

MAC, *Mycobacterium avium* complex; MSSA, methicillin-sensitive *Staphylococcus aureus*.

Characteristics of patients and factors associated with chronic *P. aeruginosa* co-infection {#s3e}
--------------------------------------------------------------------------------------------

A history of severe pneumonia, COPD or autoimmune disease including rheumatoid arthritis; the use of systemic corticosteroids and immunosuppressive agents and pulmonary *M. intracellulare* disease were significantly associated with the development of chronic *P. aeruginosa* co-infections ([table 6](#BMJRESP2014000050TB6){ref-type="table"}). The areas of lung involvement in patients with chronic *P. aeruginosa* co-infections were predominantly located in the lower lobe ([table 7](#BMJRESP2014000050TB7){ref-type="table"}). In the multivariate analysis, COPD (OR 7.5; 95% CI 2.1 to 31.4; p=0.0017) and lung involvement in the lower lobe on HRCT (OR 9.9; 95% CI 2.0 to 90.6; p=0.0027) were significantly associated with chronic *P. aeruginosa* co-infection ([table 8](#BMJRESP2014000050TB8){ref-type="table"}).

Of the 35 patients with chronic *P. aeruginosa* co-infection, 9 (25.7%) had *P. aeruginosa* detected in a MAC-positive sputum culture. Of the 24 patients with a history of MAC treatment, 18 (75%) had a positive *P. aeruginosa* sputum culture during MAC treatment. After 29 patients had a converted sputum culture of MAC, 27 (93.1%) also had a positive *P. aeruginosa* sputum culture ([tables 6](#BMJRESP2014000050TB6){ref-type="table"} and [9](#BMJRESP2014000050TB9){ref-type="table"}). Seventeen of 35 (48.6%) patients with chronic *P. aeruginosa* co-infection had received antibiotic treatment for their co-infection.

Characteristics of patients and factors associated with chronic *Aspergillus* co-infection {#s3f}
------------------------------------------------------------------------------------------

Of the 18 patients with chronic *Aspergillus* co-infection, 15 (83.3%) had a chronic necrotising pulmonary aspergillosis (CNPA), with 5 (33.3%) having pulmonary aspergilloma and 3 (16.7%) having an allergic bronchopulmonary aspergillosis (ABPA). Of the 6 patients using systemic corticosteroids, 5 had CNPA and 1 had ABPA.

Male sex; a history of severe pneumonia, asthma, tuberculosis or autoimmune disease including rheumatoid arthritis; the use of systemic corticosteroids and pulmonary *M. intracellulare* disease were significantly associated with chronic *Aspergillus* co-infection in patients ([table 6](#BMJRESP2014000050TB6){ref-type="table"}). In the multivariate analysis, the use of systemic corticosteroids (OR 7.1; 95% CI 1.2 to 50.9; p=0.034) and pulmonary *M. intracellulare* disease (OR 4.0; 95% CI 1.1 to 14.5; p=0.036) was significantly associated with chronic *Aspergillus* co-infection ([table 8](#BMJRESP2014000050TB8){ref-type="table"}).

Of the 18 patients with chronic *Aspergillus* co-infection, 9 (50%) were positive for *Aspergillus* spp at the time of MAC-positive sputum culture. Of the 11 patients with a history of MAC treatment, 9 (81.8%) had a positive *Aspergillus* sputum culture during MAC treatment. After 11 patients converted a sputum culture of MAC, 9 (81.8%) had a positive *Aspergillus* sputum culture ([tables 6](#BMJRESP2014000050TB6){ref-type="table"} and [9](#BMJRESP2014000050TB9){ref-type="table"}). Ten of the 18 (55.6%) patients with chronic *Aspergillus* co-infection had received antibiotic treatment for their co-infection.

Discussion {#s4}
==========

Previous studies in patients with bronchiectasis have shown that *H. influenzae* and *P. aeruginosa* were the more prevalent pathogens and that *S. aureus* was a less common pathogen.[@R12] [@R19] [@R24] [@R25] In contrast, a previous study in patients with bronchiectasis and NTM infection reported that *P. aeruginosa* (51%) and *S. aureus* (28%) were often isolated, whereas *H. influenzae* (12%) was rarely isolated.[@R19] As compared with these previous studies, our study showed that chronic and intermittent microorganism co-infection was observed in 45.1% and 14.9%, respectively, of patients with pulmonary MAC disease. The majority of co-infecting microorganisms were MSSA, followed by *P. aeruginosa* and *Aspergillus* spp. We found that co-infection with *Aspergillus* spp is the third most prevalent infection in patients with pulmonary MAC disease.

CNPA was occasionally complicated during a long course of MAC disease.[@R26] Kunst *et al* reported that *Aspergillus*-related lung disease was more common in patients with bronchiectasis and NTM. Although they used serological markers but not sputum culture for the diagnosis of *Aspergillus*-related lung disease, they showed that NTM infection predisposed patients with bronchiectasis to *Aspergillus*-related lung disease.[@R20] In this study, most of our participants had bronchiectasis, and all 18 patients with chronic *Aspergillus* infection had culture-proven *Aspergillus*-related lung disease (15 patients with CNPA and 3 patients with ABPA).

In patients with cystic fibrosis, chronic Methicillin-resistant *Staphylococcus aureus* (MRSA) infection caused a rapid decline in lung function, and chronic *Aspergillus* infection was more frequently associated with both low lung function and increased risk of hospitalisation than intermittent *Aspergillus* infection or no infection.[@R17] [@R18] In patients with bronchiectasis, the baseline lung function of patients with chronic *P. aeruginosa* infection was lower than that of patients either with intermittent *P. aeruginosa* infection or without an infection.[@R16] Others reported that chronic *P. aeruginosa* infection was associated with an accelerated decline in lung function.[@R13] [@R27] Therefore, we divided our group of co-infected patients into those with chronic co-infections and those with intermittent co-infections. In this study, we found that these three microorganisms were predominantly isolated from chronically co-infected patients (71.9% with an MSSA infection, 77.8% with a *P. aeruginosa* infection and 62.1% with an *Aspergillus* infection).

Previous studies have demonstrated that the risk factors for microorganism infection in patients with bronchiectasis and cystic fibrosis include COPD,[@R21] rheumatoid arthritis,[@R22] a long duration of the disease[@R12] and the use of immunosuppressive agents.[@R18] [@R22] Compared with these previous studies, our study found that patients with COPD were at an increased risk of chronic infection with any pathogenic microorganisms or with MSSA or *P. aeruginosa* individually. A long duration of MAC disease (≥8 years) was significantly associated with chronic MSSA co-infection. The use of systemic corticosteroids was significantly associated with chronic *Aspergillus* spp co-infection. These factors for microorganism co-infection in patients with pulmonary MAC disease are similar to those in patients with bronchiectasis and cystic fibrosis.

Since COPD and systemic corticosteroid use also increased the risk of pulmonary NTM disease,[@R28] close attention to pulmonary MAC disease and other co-infections is needed in these patients.

A recent study comparing the features of patients with pulmonary *M. avium* and *M. intracellulare* disease showed that patients with pulmonary *M. intracellulare* disease had more severe symptoms including the FC form of the disease and a worse prognosis.[@R5] In this study, we found that pulmonary *M. intracellulare* disease was significantly associated with intermittent co-infection and chronic co-infection, especially *Aspergillus* co-infection. Patients with pulmonary *M. intracellulare* disease more frequently had the host traits of severe pneumonia, malignant disease and autoimmune disease, systemic corticosteroid use and more cavity findings (FC form and NB+FC form) in the HRCT than patients with pulmonary *M. avium* disease ([table 2](#BMJRESP2014000050TB2){ref-type="table"}). Therefore, patients with pulmonary *M. intracellulare* disease potentially may have more lung deterioration than patients with pulmonary *M. avium* disease and thus be predisposed to the development of microorganism co-infection.

In our study participants, clarithromycin, rifampicin and ethambutol were the most commonly used drugs for MAC treatment. The historical use of these antibiotics in patients with MAC disease did not differ among patients with MSSA, *P. aeruginosa* and *Aspergillus* co-infections ([table 6](#BMJRESP2014000050TB6){ref-type="table"}). However, since clarithromycin and rifampicin decrease susceptibility to MSSA, MAC treatment markedly suppressed the sputum isolation of MSSA but only during MAC treatment. In contrast, *P. aeruginosa* and *Aspergillus* were isolated during MAC treatment due to the lack of susceptibility of *Pseudomonas* and *Aspergillus* to these drugs.

Recently, Binder *et al*[@R31] reported that cystic fibrosis patients with MAC were less likely than those without MAC to be colonised with *P. aeruginosa*. Winthrop *et al* also showed that non-cystic fibrosis bronchiectasis patients with NTM were less likely than those without NTM to be colonised with *Pseudomonas* spp as indicated in the US Bronchiectasis Registry.[@R32] In this study, MSSA was similarly isolated in MAC-positive sputum cultures and after MAC sputum conversion ([table 9](#BMJRESP2014000050TB9){ref-type="table"}). However, we found that *P. aeruginosa* was less frequently isolated from positive MAC sputum cultures and more often isolated after MAC sputum conversion ([tables 6](#BMJRESP2014000050TB6){ref-type="table"} and [9](#BMJRESP2014000050TB9){ref-type="table"}). Although we investigated only patients with pulmonary MAC disease and did not include patients without MAC disease in this study, we found that *P. aeruginosa* was increasingly isolated after negative sputum conversion of MAC in patients who were originally MAC-positive and that *P. aeruginosa* was less likely to be isolated concurrently with MAC. Therefore, our data support these previous studies.[@R31] [@R32]

The existence of lung nodules was associated with chronic MSSA co-infection in this study. Morikawa *et al* previously reported that centrilobular nodules (63.9%) were more common than consolidation (51.8%) and bronchiectasis (12.0%) in patients with MSSA pneumonia. Since MSSA was rarely isolated during the antibiotic treatment of MAC in this study, some of the nodules found in patients with chronic MSSA co-infection might have been associated with MSSA pneumonia.[@R33]

Patients with chronic *P. aeruginosa* infection had greater areas of lung involvement in the lower lobes than patients without co-infection in this study. Previous studies showed that *P. aeruginosa* pneumonia was predominantly involved in the lower lung zone.[@R34] [@R35] Even after negative sputum conversion of MAC, *P. aeruginosa* remained positive in sputum cultures ([table 9](#BMJRESP2014000050TB9){ref-type="table"}), and these areas of lower lung involvement were observed in follow-up CTs (data not shown). Therefore, some of the areas of lower lobe involvement in patients with chronic *P. aeruginosa* infection were most likely due to *P. aeruginosa* infection.

This study had the limitation of retrospective observation. We could not regularly follow sputum examination or chest CT evaluation for every participant. More than half of the patients were excluded from our cohort due to missing sputum examinations and chest CT evaluations. These excluded patients might have had a different frequency of microorganism isolation from the participants in this study. Therefore, the recruitment of additional patients and collection of additional sputum samples might allow more pathogenic microorganisms to be isolated and thus alter the prevalence of specific co-infections. However, since most of the excluded patients had few symptoms and less expectoration of sputum, the results in this study would reflect a symptomatic population. Also, since the university hospital is the tertiary referral hospital, more patients with severe conditions or with multiple complications are likely to be referred. Furthermore, this study was conducted only at a single centre. These may cause the patient selection bias. In this study, multiple statistical tests were applied to the different co-infection subgroups, and this carries a risk of false-positive associations---hence, the findings of this subgroup analysis should be viewed as hypothesis-generating rather than definitive. Finally, since we did not analyse an association of co-infection with the outcome or prognosis, we could not show the clinical significance of co-infection in this study.

In conclusion, we showed a high prevalence of chronic co-infections of pathogenic microorganisms in patients with pulmonary MAC disease. MSSA, *P. aeruginosa* and *Aspergillus* were the most prevalent isolated microorganisms. COPD and pulmonary *M. intracellulare* disease were risk factors for chronic co-infection.
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